Kirpal Kooner The opportunity The investment thesis in CAPREIT (TSX:CAR.UN:CA) concerns the Canadian housing sector and its current affordability crisis. A specific mix of demographic, regulatory, and economic conditions has aligned to create a favorable environment for residential rental properties and apartment REITs. The demographic tailwind There is a saying in Canada that it takes five minutes for a family to arrive in Canada, and seven years for the country to build them a home. According to Stati ...

Core Thesis - The investment thesis for Canadian Apartment Properties Real Estate Investment Trust (CAPREIT) is based on compelling valuation and strong tailwinds that offset interest rate pressures, leading to a Buy rating after 18 months of being on the sidelines [2][27] - CAPREIT has delivered a total return of 10.79%, approximately double that of the iShares S&P/TSX Capped REIT ETF [2] Q1-2024 Performance - In Q1-2024, CAPREIT reported an occupancy rate of 98.4% and a stable overall NAV, with net operating income (NOI) increasing by 7.3% [7][9] - The occupied average monthly rent rose by 6.5% to $1,539, while NOI margins improved to 61.9% [9][10] Rental Dynamics - The weighted average increase in rents on suite turnovers was 23.2%, indicating strong demand despite modest increases on lease renewals due to rent control [14][19] - The gap between in-place rents and market rents provides a clear growth trajectory for CAPREIT, with expectations of same property NOI growth of at least 5% annually [20] Market Context - Canada is experiencing rapid population growth through immigration, contributing to a challenging housing market with limited new construction [20][22] - Despite the difficult market conditions, CAPREIT is positioned as a strong investment opportunity, with a well-balanced mortgage portfolio and a debt maturity profile that is less problematic than a year ago [22][23] Future Outlook - The expectation is for CAPREIT's stock price to reach at least $60 over the next five years, even without further interest rate cuts, making it an appealing long-term investment [27]

Company Announcement - Avis Budget Group, Inc. plans to report its second quarter 2024 results after the market close on August 5th, 2024 [1] - A conference call for institutional investors to discuss these results is scheduled for August 6th, 2024 at 8:30 a.m. Eastern time [1] - Investors can access the call via the company's investor relations website or by dialing a designated phone number [1] Company Overview - Avis Budget Group is a leading global provider of mobility solutions with approximately 10,250 rental locations in around 180 countries [2] - The company operates its car rental offices primarily in North America, Europe, and Australasia, while using licensees in other regions [2] - The Zipcar brand, part of Avis Budget Group, is recognized as the world's leading car sharing network [2]

PARSIPPANY, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2024 results after the market close on Monday, August 5th, 2024, and to host a conference call for institutional investors to discuss these results on Tuesday, August 6th, 2024 at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encouraged to dial in approximately 10 minutes prior to th ...

Core Insights - Immix Biopharma has initiated the U.S. NEXICART-2 trial for NXC-201, a CAR-T cell therapy targeting AL Amyloidosis, with the first patient dosed at Memorial Sloan Kettering Cancer Center [1][3] - The NEXICART-2 study aims to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL Amyloidosis patients, building on positive results from the NEXICART-1 trial which reported a 92% overall response rate [2][4] - NXC-201 is the only CAR-T therapy currently in development for AL Amyloidosis, with the potential to become a first-in-class treatment [3][7] Company Overview - Immix Biopharma is a clinical-stage biopharmaceutical company focused on cell therapies for AL Amyloidosis and autoimmune diseases, with NXC-201 as its lead candidate [9] - The company has received Orphan Drug Designation for NXC-201 in both the U.S. and EU [7][9] Clinical Trials - NEXICART-2 is a Phase 1b/2 trial designed to enroll 40 patients with adequate cardiac function who have not received prior BCMA-targeted therapy, evaluating two doses of NXC-201 [4] - The primary endpoints of the trial include complete response rate and overall response rate, following consensus recommendations [4] Market Context - The prevalence of relapsed/refractory AL Amyloidosis in the U.S. is estimated to grow at 12% per year, reaching approximately 33,277 patients in 2024 [8] - The amyloidosis market was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025 [8]

Core Insights - Senti Biosciences, Inc. has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of its investigational cell therapy SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][2] - The ongoing Phase 1 clinical trial of SENTI-202 is evaluating two dose levels (1 billion or 1.5 billion cells) and aims to provide initial efficacy data by the end of 2024 and durability data in 2025 [1][2] Company Overview - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision and control in targeting cancer cells while sparing healthy cells [6] - The company is leveraging off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells outfitted with Gene Circuits to address challenging liquid and solid tumor indications [6] Product Details - SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while protecting healthy bone marrow cells [3] - The therapy incorporates an OR GATE for activating CAR targeting CD33 and FLT3, a NOT GATE to protect healthy cells, and calibrated-release IL-15 technology to enhance cell persistence and activity [3] Clinical Trial Information - The Phase 1 trial (NCT06325748) is currently enrolling adult patients with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies at multiple sites in the U.S. and Australia [2][3] - Patients may receive multiple treatment cycles based on safety and efficacy data, with each cycle consisting of three doses administered weekly [2] Market Context - Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, with an estimated 20,800 new cases in the U.S. in 2024 and a five-year survival rate of approximately 30% [5] - Current treatment options for relapsed or refractory AML are limited, with a median overall survival of less than seven months [5]

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination triggers a $2 million milestone payment to CarismaPHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration ...

Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; ...

This patient is expected to be the final patient in the second dosage cohort of the trialSAN JOSE, Calif., June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. This patient is expected to be the last patient in the seco ...

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune diseaseKYV-101 is a fully human anti-CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseasesEMERYVILLE, Calif., June 20, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from auto ...